Answer
Zynlonta (loncastuximab tesirine) is contraindicated in patients with hypersensitivity to loncastuximab tesirine or any excipient listed in section 6.1 of its SmPC.
Sources for this answer
- Zynlonta, 10mg, powder for concentrate for solution for infusionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.3 Contraindications · Version 8Document updated
Sources checked